Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

BioArctic signed the first deal for its “brain transporter” with Bristol Myers Squibb late last year. The deal is worth up to $1.4bn and allows the US drugmaker to start trials using the technology to ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...

The Western New York Chapter of the Alzheimer’s Association will offer two free programs in the area next week — one on ...